TABLE 2.
VE and Duration of Protection among Children Who Received at Least 1 Dose of RV5 or RV1 Versus Unvaccinated Children by Age*
| Health Care Utilization Rate, n/10,000 | Health Care Utilization Rate, n/10,000 | |||||
|---|---|---|---|---|---|---|
| RV5 | Unvaccinated‡ | VE (95% CI), % | RV1 | Unvaccinated§ | VE (95% CI), % | |
| Rotavirus-coded hospitalizations | ||||||
| 3–11 | 0.88 | 7.34 | 88 (86–90) | 0.75 | 5.83 | 87 (80–91) |
| 12–23 | 2.04 | 25.31 | 88 (86–90) | 0.89 | 22.99 | 86 (80–91) |
| 24–35 | 1.28 | 10.78 | 87 (85–89) | 5.97 | 9.76 | 86 (79–91) |
| 36–47 | 0.17 | 4.88 | 87 (85–89) | 0.00 | 4.94 | NA |
| 48–59 | 2.33 | 3.15 | 87 (85–89) | 0.00 | 2.56 | NA |
| Diarrhea-associated Hospitalizations | ||||||
| 3–11 | 39 | 59 | 43 (40–45) | 37 | 57 | 41 (36–46) |
| 12–23 | 64 | 134 | 43 (40–45) | 66 | 144 | 42 (37–46) |
| 24–35 | 36 | 76 | 42 (40–45) | 40 | 87 | 41 (36–46) |
| 36–47 | 28 | 53 | 43 (40–45) | 19 | 64 | 41 (35–46) |
| 48–59 | 23 | 32 | 42 (39–44) | 23 | 40 | 41 (34–46) |
| Diarrhea-associated emergency departments | ||||||
| 3–11 | 203 | 245 | 23 (22–25) | 194 | 244 | 24 (21–26) |
| 12–23 | 382 | 575 | 23 (22–25) | 451 | 641 | 24 (21–26) |
| 24–35 | 246 | 412 | 24 (22–25) | 264 | 503 | 24 (21–26) |
| 36–47 | 189 | 276 | 25 (23–26) | 205 | 358 | 27 (24–29) |
| 48–59 | 179 | 263 | 25 (23–26) | 193 | 376 | 25 (22–29) |
| Diarrhea-associated outpatient visits | ||||||
| 3–11 | 1511 | 1343 | −4 (−5 to −3) | 1472 | 1317 | −5 (−7 to −4) |
| 12–23 | 2790 | 2786 | −4 (−5 to −3) | 2961 | 3047 | −5 (−6 to −4) |
| 24–35 | 1752 | 1863 | −3 (−4 to −3) | 2002 | 2185 | −4 (−6 to −3) |
| 36–47 | 1187 | 1266 | −2 (−3 to −1) | 1386 | 1586 | −2 (−4 to −1) |
| 48–59 | 965 | 1216 | −2 (−3 to −1) | 1371 | 1683 | −3 (−4 to −1) |
CI, confidence interval; NA, not applicable; PY, person-year.
Vaccination status was determined by the presence or absence of a current procedural terminology code for receipt of at least 1 dose of RV5. Children who were either from states with universal vaccination programs or had received mixed vaccine schedules with both RV1 and RV5 doses were excluded.
Age at hospitalization for a diarrhea-associated event.
Children who were age-eligible for the RV5 vaccine as of February 3, 2006, when RV5 was first recommended (ie, age less than the first-dose upper limit of 14 wk and 6 d when RV5 was licensed on February 3, 2006) and who were continuously enrolled in their insurance plan for at least 3 mo.
Children who were age-eligible for the RV1 vaccine as of April 3, 2008, when RV1 was first recommended (ie, age less than the first-dose upper limit of 12 wk (previous recommendation) when RV1 was licensed on April 3, 2008) and who were continuously enrolled in their insurance plan for at least 3 mo.